Anti-pd-1 antibodies and their uses

Abstract

The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.

1 .- 21 . (canceled) 
     
     
         22 . A method of treating a cancer, comprising administering to a patient in need thereof a therapeutically effective amount of an anti-PD-1 binding protein, wherein the binding protein comprises (i) a V H  chain comprising three CDRs; and (ii) a V L  chain comprising three CDRs, wherein: 
       
         
           
                 
                 
               
                     
                   V H  CDR#1 is 
                 
                     
                   (SEQ ID NO: 11) 
                 
                     
                   GYTFTHYGMN; 
                 
                     
                     
                 
                     
                   V H  CDR#2 is 
                 
                     
                   (SEQ ID NO: 12) 
                 
                     
                   WVNTYTGEPTYADDFKG; 
                 
                     
                     
                 
                     
                   V H  CDR#3 is 
                 
                     
                   (SEQ ID NO: 13) 
                 
                     
                   EGEGLGFGD; 
                 
                     
                     
                 
                     
                   V L  CDR#1 is 
                 
                     
                   (SEQ ID NO: 14) 
                 
                     
                   RSSQSIVHSHGDTYLE; 
                 
                     
                     
                 
                     
                   V L  CDR#2 is 
                 
                     
                   (SEQ ID NO: 15) 
                 
                     
                   KVSNRFS; 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   V L  CDR#3 is 
                 
                     
                   (SEQ ID NO: 16) 
                 
                     
                   FQGSHIPVT. 
                 
             
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         23 . The method of  claim 22 , wherein the cancer is selected from bladder cancer, breast cancer, head and neck cancer, kidney cancer, lung cancer, lymphoma, melanoma, and stomach cancer. 
     
     
         24 . The method of  claim 23 , wherein the lung cancer is non-small cell lung cancer. 
     
     
         25 . The method of claim  21 , in which the anti-PD-1 binding protein is administered intravenously.